Please Wait

Applying Filters...

Ceftazidime
KDMF
Table View

Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Ceftazidime

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

40 API Suppliers, 18 USDMF, 16 CEP/COS, 6 JDMF, 4 EU WC, 4 KDMF, 4 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

222 FDF Dossiers, 42 FDA Orange Book, 100 Europe, 6 Canada, 16 South Africa, 58 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 0.5GM BASE;2GM/VIAL, INJECTABLE;INJECTION - 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 6GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 20MG BASE/ML, INJECTABLE;INJECTION - EQ 40MG BASE/ML, INJECTABLE;INJECTION - EQ 1GM BASE, INJECTABLE;INJECTION - EQ 2GM BASE

RELATED EXCIPIENT COMPANIES

1 Actylis, 1 Kerry, 1 Microlex e.U, 1 Pluviaendo, 1 Roquette

EXCIPIENTS BY APPLICATIONS

2 Parenteral, 2 Fillers, Diluents & Binders, 1 Taste Masking, 1 Co-Processed Excipients

DIGITAL CONTENT

25 News #PharmaBuzz

25 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 82 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

22 APIs, 20 FDF Dossiers

PATENTS & EXCLUSIVITIES

10 US Patents, 4 US Exclusivities, 16 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 2 USP, 4 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/03/2025	ACS DOBFAR SPA	Italy	Korea Pfizer Pharmaceutical Co., Ltd.	20221222-210-J-1424	Ceftazidime hydrate and dried sodium carbonate	2022-12-22	ACS Dobfar SpA@ACS DOBFAR SpA	Italy	Viale Addetta, 2a/12–3/5, 20067 Tribiano (MI), Italy@Via Marzabotto, 1, 7/9 20871 Vimercate (MB), Italy
28/03/2025	Hanmi Pharmaceutical	South Korea	Hanmi Precision Chemical Co., Ltd.	20200120-210-J-541	Septazidim Hydrogen Cargo	2020-01-20	Hanmi Precision Chemical Co., Ltd.	South Korea	57 Gyeongje-ro, Siheung-si, Gyeonggi-do

Contact us
to update this info

Ceftazidime

Ceftazidime

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

40 API Suppliers

18 USDMF

16 CEP/COS

6 JDMF

4 EU WC

4 KDMF

4 NDC API

15 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

222 FDF Dossiers

42 FDA Orange Book

100 Europe

6 Canada

16 South Africa

58 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 0.5GM BASE;2GM/VIAL

INJECTABLE;INJECTION - 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 6GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 20MG BASE/ML

INJECTABLE;INJECTION - EQ 40MG BASE/ML

INJECTABLE;INJECTION - EQ 1GM BASE

INJECTABLE;INJECTION - EQ 2GM BASE

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Kerry

1 Microlex e.U

1 Pluviaendo

1 Roquette

EXCIPIENTS BY APPLICATIONS

2 Parenteral

2 Fillers, Diluents & Binders

1 Taste Masking

1 Co-Processed Excipients

DIGITAL CONTENT

25 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

82 Regulatory FDF Prices

8 Annual Reports

MARKET PLACE

22 APIs

20 FDF Dossiers

PATENTS & EXCLUSIVITIES

10 US Patents

4 US Exclusivities

16 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM

2 USP

4 Others

Filters

INJECTABLE;INJECTION - 1GM/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 2GM/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 500MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 6GM/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons